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Covalent histone modifications clearly play an essential role in ligand-dependent transcriptional reg-
ulation by nuclear receptors. One of the predominant mechanisms used by nuclear receptors to
activate or repress target-gene transcription is the recruitment of coregulatory factors capable of
covalently modify the amino terminal ends of histones. Here we show that the thyroid hormone (T3)
produces a rapid increase in histone H3Ser10 phosphorylation (H3Ser10ph) concomitant to the rapid
displacement of the heterochromatin protein 1 (P1) to the nuclear periphery. Moreover, we
found that T3-mediated pituitary gene transcription is associated with an increase in H3Ser10ph.
Interestingly, theAurora kinase B inhibitor ZM443979 abolishes the effect of T3 onH3Ser10ph, blocks
HP1 delocalization, and significantly reduces ligand-dependent transactivation. Similar effects were
shownwhenAurora kinase B expressionwas abrogated in small interferingRNAassays. In an effort to
understand the underlyingmechanism bywhich T3 increases H3Ser10ph, we demonstrate that ligan-
ded thyroid hormone receptor directly interacts with Aurora kinase B, increasing its kinase activity.
Moreover, using chromatin immunoprecipitation assays, we have shown that Aurora kinase B partic-
ipates of a mechanism that displaces HP1 from promoter region, thus preparing the chromatin for
the transcriptional activationof T3 regulatedgenes.Our findings reveal a novel role forAurora kinase
B during transcriptional initiation in GO/G1, apart from its well-known mitotic activity. (Molecular
Endocrinology 25: 385–393, 2011)
NURSA Molecule Pages: Nuclear Receptors: TR-; Ligands: Thyroid hormone.
In eukaryotic cells, genes are complexed with core his-tones and other chromosomal proteins to form either
active euchromatin or silent heterochromatin (1–3). The
tails of core histones are subjected to covalent posttrans-
lational modifications which allow the recruitment of
proteins such as heterochromatin protein (HP1) that
modulate chromatin structure (4). In mammalian cells,
HP1 is present both in pericentric heterochromatin and
in euchromatin where it represses gene expression (5),
while HP1 and HP1 are mainly associated with either
constitutive heterochromatin or euchromatin, respec-
tively. In histones H3 andH4, both lysine acetylation and
serine phosphorylation are associated with transcrip-
tional activation, while lysine methylation at specific res-
idues is linked to either transcriptional repression or
activation. Lysine residues in histone tails can be mono-, di-
or trimethylated by the action of histonemethyltransferases.
Methylation of the lysine 9 residue in H3 (H3K9me), par-
ticularly in the di- and trimethylated state, serves as a scaf-
fold for HP1 proteins binding to the chromatin. It has been
demonstrated that HP1 bound to methylated H3K9 is re-
leased from chromatin by H3Ser10 phosphorylation. This
“methyl-phos switch”mechanism occurs at the onset of mi-
tosis and is regulated by Aurora kinase-B (6, 7). The role of
Aurora kinase B during mitosis is well established as chro-
mosome passenger protein kinase that regulates centrosome
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separation, chromosome segregation, and cytokinesis.
However, an additional report shows that Aurora kinase B
also mediates the displacement of HP1 from facultative
heterochromatin by Ser10 phosphorylation in terminally
differentiated post-mitotic plasma cells suggesting that the
“methyl-phos” switch mechanism could occur in other cell-
cycle stages apart from mitosis.
Nuclear receptors constitute a family of ligand-depen-
dent transcription factors that fulfill important roles in
growth, development, and metabolism. Thyroid nuclear re-
ceptors (TRs) belong to this family and are activated upon
the binding of thyroid hormone (T3). In the absence of li-
gand, TRs recruit corepressor complexes that contain his-
tone deacetylases (8, 9). Ligand binding allows the release of
corepressors and the recruitment of coactivators, some of
which contain histone acetyltransferases. Gene expression
results from the ability of transcription activators and re-
pressors to access chromatin at specific promoter. Interest-
ingly Aurora kinase B activity and histone posttranslational
modifications have been previously related with the action
of nuclear receptors. Thus, estrogens regulateH3Ser10ph in
both ovarian follicle andmammary epithelial tumor cells by
induction of Aurora kinase B activity
(10). Other ligands such as T3 activate
transcriptionwith an increase in the dual
modification H3Ser10pH/H3K14 al-
though the underlying mechanism has
yet to be elucidated.
T3 is an important regulator of pi-
tuitary genes such as GH and prolac-
tine (PRL) genes. Both are expressed in
GH4C1 cells, a pituitary somatolacto-
trope cell line, which is derived from a
rat pituitary tumor that has been
widely used as a model to study the
mechanism of T3 action (11). In this
system, here we show that T3 causes a
rapid increase in the total cellular lev-
els of H3Ser10 phosphorylation ac-
companied by HP1 delocalization to
the nuclear periphery. Inhibition of
Aurora B blocks this effect and inhibits
T3-dependent gene expression, dem-
onstrating a novel mechanism by
which this enzyme plays an important
role in the initiation of hormone-de-
pendent gene activation. In addition to
its functions during mitosis, the Au-
rora kinase B has an important role in
the initiation of gene transcription by
interaction with TR in a ligand depen-
dent manner. Our results also suggest
that thyroid receptors are important
regulators of the uncoupling of Aurora kinase B regu-
lation from the cell cycle.
Results
T3 induces HP1 redistribution to the nuclear
periphery and increases global cellular levels
of H3Ser10ph
To determine whether T3 controls HP1-mediated gene
regulation, we first analyzed HP1 localization by immu-
nofluorescence microscopy in pituitary GH4C1 cells
which express high levels of TR. As expected (12–15),
endogenous HP1 localized as condensed region into the
nucleus of untreated cells grown for 48 h in hormone-
depleted serum. In contrast, exposure to T3 for only 15
min caused the relocation of HP1 to the periphery of the
nucleus (Fig. 1A). To demonstrate that TRwas implicated
in this effect we overexpressed both TR and HP1 in
HEK293T cells, in which TR levels are almost undetect-
able. After T3 treatment, HP1 only relocated to the nu-
clear envelope in those cells cotransfected with both plas-
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FIG. 1. HP1 redistribution and levels of H3Ser10ph after T3 treatment. A, Endogenous Hp1 is
relocalized in GH4C1 cells treated with T3 (5 nM). B, Simultaneous expression of pSG5-TR with
hemaglutinin (HA)-tagged Hp1 expression in HEK293T cells leads to Hp1 redistribution after
incubation with T3 (100 nM) for 15 min. C, Total cellular levels of H3Ser10ph in T3-treated GH4C1
cells. H3 was used as a loading control. D, Immunofluorescence of endogenous H3Ser10ph in
GH4C1 cells treated with T3 for 15 min. E, Incubation of GH4C1 cells with 100 nM estradiol for 5
or 15 min increases total cellular levels of H3Ser10 phosphorylation.
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mids, indicating that this effect was indeed mediated by
the receptor (Fig. 1B).
Because the H3 phosphorylation at Ser10 has been
shown to prevent HP1 binding to di- and trimethylated
H3K9 (16), we next analyzed the effect of T3 onH3Ser10
phosphorylation. As shown by Western blot assays, T3
caused a rapid increase of H3Ser10ph in GH4C1 cells
(Fig. 1C). To confirm this data we performed immuno-
fluorescence assays after 15 min of T3 treatment (Fig.
1D). As expected, these assays also showed an increase in
the intensity of staining H3Ser10ph and demonstrated
that its dispersed nuclear distribution was not altered
in hormone-treated cells. Because estrogens increase
H3Ser10ph in other models and GH4C1 cells contain
endogenous estrogens receptor levels, we also checked
whether the observed effects were nuclear receptor spe-
cific. For that reason we analyzed the effect of 5- and
15-min estrogens treatment on H3Ser10ph levels in
GH4C1 cells (Fig. 1E). In agreement with the effect ob-
served after T3 incubation, estrogens also produced a
rapid increase on H3Ser10ph in this cell line.
T3 increases H3Ser10ph levels at T3-
target promoters
Given the fact that we observed a global increase in
H3Ser10ph levels after 15-min T3 treatment, we tested
the possibility that this posttransla-
tional modification could be found at
target genes upon hormonal induction.
Thus, we performed chromatin immu-
noprecipitation (ChIP) assays with the
promoter region of theGH gene which
contains thyroid hormone response el-
ements (TREs). In agreement with pre-
vious reports (17), a small amount of
TR was bound to GH promoter in the
absence of hormone, while short-term
exposure to T3 (15 min) provoked a
significant recruitment of TR to the
promoter (Fig. 2A). In parallel to the
TR binding, a significant increase in
H3Ser10ph marker was observed after
T3 treatment, indicating an increase of
this modification during hormonal ac-
tivation of transcription.
PRL gene is also a target of T3 acti-
vation, so we also checked the levels of
H3Ser10ph after T3 induction in the
PRL promoter containing TREs. As it
can be observed in Fig. 2B, T3 treat-
ment also produced an increase in the
recruitment of TR to the PRL promoter
together with an important increase in
H3Ser10ph levels. In contrast, when we analyzed the lev-
els of this epigenetic mark in GAPDH promoter, which
does not contain TREs, we did not observe any change
upon T3 treatment (Fig. 2C).
Aurora kinase B is required for T3-induced HP1
displacement and H3Ser10ph increase
The effect of T3 on H3 phosphorylation could be at-
tributable to the activation of several kinases such as
mitogen- and stress-associated protein kinase 1 (MSK1),
ribosomal S6 kinases (RSK)1-2, and even to the effect
controlled by Aurora kinase B where H3Ser10 phosphor-
ylation at the onset of mitosis interferes with the interac-
tion of HP1 with trimethylated H3K9 (6, 7). In addition,
it has been reported that phosphorylation of Ser10 also
markedly decreased the in vitro interaction of HP1with
both K9me3 and K9me2 peptides (16). For these reasons,
we next analyzed the possible role of Aurora kinase B in
the effect of T3 on both H3Ser10ph and displacement of
HP1. We found that T3-induced phosphorylation on
H3Ser10was blocked either by incubation in the presence
of the specific Aurora kinase B inhibitor, ZM447439 (Fig.
3A), or knocking-down Aurora kinase B expression with
specific small interfering RNA (siRNA) (Fig. 3B). More-
over, exposure to ZM447439 also inhibited the T3-in-
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FIG. 2. T3-regulated genes showed increased levels of H3Ser10ph after 15-min treatment
with 5 nM T3. A, Representative ChIP assay in GH4C1 cells using the indicated antibodies and
primers flanking the TRE region of the GH promoter (left). Real-time quantitative PCR (QRT-
PCR) of several ChIP assays (right). Bars represent mean  SD (n  3). ChIP assays were
performed in GH4C1 cells maintained in the presence and absence of T3 (5 nM, 15min). B
and C, Immunoprecipitated chromatin was quantified by real-time PCR using primers flanking
the TRE element in the Prolactin gene and GAPDH gene primers that was used as negative
control. Bars represent mean  SD (n 3).
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duced displacement of HP1 to the periphery of the nu-
cleus (Fig. 3C). These data indicate that Aurora kinase B
mediates the effect of T3 on HP1 localization.
We wanted to check whether MSK1 or RSK1-2 was
also involved in T3-mediated H3Ser10ph increase. H89
as well as Ro318220 are used to inhibit both activities,
respectively, but still inhibit two or more protein kinases
with similar potency. However, MSK1 respond to both
mitogen- and stress-activated protein kinases (ERK and
p38MAPK), while RSK1-2 is ERK target. In cell-based
assays, it has been shown that these MAPK are specifi-
cally inhibited by U0126 and SB203580, respectively
(18). Thus, we incubated GH4C1 cells in the absence or
presence of both specific inhibitors. Figure 3D shows that
none of them were able to avoid H3ser10ph increase in-
duced by thyroid hormone. These data demonstrate that
T3 effect is specifically mediated by Aurora kinase B in
our cells.
A particularly striking aspect of these results is the fact
that T3 effects occurred in cells that do not proliferate.
Cell cycle analysis showed that 80–90% of GH4C1 cells
incubated in hormone-depleted medium for 24 h re-
mained in G0/G1 phase, and incubation with T3 for up to
8 h did not induce the entry of the cells in the G2/M phase
(Fig. 4). This result implies a novel role for Aurora Kinase
B at G0/G1, apart from its well-known mitotic function.
TR interacts with Aurora kinase B
and increases its kinase activity in
a T3-dependent manner
To further study the mechanism un-
derlying the effect of T3 on H3Ser10ph
and HP1 delocalization, we analyzed
the interaction of TR with Aurora
kinase B. In vitro pull-down assays
showed that Aurora kinase B interacted
with TR both in the absence or pres-
ence of T3 (Fig. 5A). Despite the T3-
induced increase in H3Ser10ph, the
interaction between TR and Aurora ki-
nase Bwas notmodified by exposure to
the hormone. The interaction between
both proteins was confirmed by coim-
munoprecipitation assays in GH4C1
cells (Fig. 5B). Throughout the same
experiment, we tested the kinase activ-
ity of Aurora kinase B in the immuno-
precipitates from control and T3-
treated cells (Fig. 5B). T3 augmented
significantly the kinase activity of Au-
rora kinase B, as reflected by the Ser10
phosphorylation of exogenousH3 used
as a substrate.
Aurora B is required for transcriptional activation
of T3-responsive genes
Our results indicate that the effect of T3 on the asso-
ciation of HP1 with chromatin appears to be regulated
by a novel mechanism involving Aurora kinase B (Figs. 3
and 5). To test whether Aurora kinase B modulated TR
transcriptional activity, a TRE-containing luciferase con-
struct (DR4-luc) was transiently transfected into GH4C1
cells. As expected, T3 strongly induced the DR4-luc ac-
tivity in control cells. However, the incubation of the cells
with ZM447439 significantly reduced the T3-mediated
transactivation of this reporter (Fig. 6A). Similarly, this
inhibitor severely impaired T3-stimulated transcription
of the endogenousGH gene (Fig. 6B). In addition, ectopic
expression of Aurora kinase B increased in a dose-depen-
dent manner T3–dependent transactivation in HEK293T
cells (Fig. 6C), whereas a “kinase-dead” Aurora kinase
B construct (K109R) had no effect on the reporter gene
(Fig. 6D).
To determine whether Aurora kinase B and TR asso-
ciate in a ligand-dependent manner with chromatin in
vivo, we next performed ChIP assays on T3-treated
GH4C1 cells (Fig. 6E). In these cells, both TR and Aurora
kinase B were rapidly recruited to the GH promoter in a
hormone-dependent manner. The data suggest that both
siRNA 
AK-B
    -      +        -      +    T3
  α-H3
  α-H3S10ph
 -      +      -     +     T3  
 -      -      +     +    ZM
  α-AK-B
C
T3
  C
+Z
M
  T
3+
ZM
DAPIα-HA
B
C
  α-H3
  α-H3S10ph
siRNA 
control
A
D
 -      +       -     +      -      +   T3 
  
     
SB203580  U0126 DMSO
  α-H3S10ph
  α-H3
FIG. 3. Inhibition of Aurora-B abolishes both the delocalization of Hp1 and H3Ser10ph
induced by T3. A, H3Ser10ph levels in GH4C1 cells incubated with or without T3 and
ZM447439. B, Aurora kinase B and H3Ser10ph protein expression in GH4C1 cells
transfected with siRNA targeting Aurora kinase B or a control siRNA. C, Nuclear
localization of HP1 in HEK293T after ectopic expression of pSG5-TR together with
hemaglutinin (HA)-tagged HP1. Cells were treated with ZM447439 in absence or
presence of T3. D, H3Ser10ph levels in GH4C1 cells incubated in the presence or absence
of T3 and DMSO, SB203580 or U0126.
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the T3-mediated association of Aurora kinase B with the
GH promoter and the increase in its kinase activity causes
the enrichment observed in H3Ser10ph after T3 treat-
ment (Fig. 6E). Interestingly, the association of Hp1
with the promoter strongly diminished after exposure to
T3. Thus, T3 induces phosphorylation of the Ser10 resi-
due in H3 and causes displacement of HP1 from the
promoter in a mechanism regulated by Aurora kinase B.
Discussion
Thyroid hormone regulates HP1 dissociation
through histone covalent modifications
The results of this study point at the important role
of thyroid hormone in the regulation of chromatin struc-
ture, secondary to the modulation of specific epigenetic
changes in certain histone residues. Histones are subject
to numerous posttranslational modifications that corre-
late with the state of higher-order chromatin structure
and gene expression. At the moment, it is not clear
whether these epigenetic marks are causative regulatory
factors in chromatin structure changes, although it has
been evidenced that modulation of H3Ser10 phosphory-
lation at interphase can function as a causative regulator
of higher-order chromatin structure in Drosophila in vivo
(19). Here we report that thyroid hormone receptor, in
the presence of its ligand, produces the delocalization of
HP1 protein to the nuclear periphery, concomitant with
a significant and rapid increase in H3Ser10 phosphoryla-
tion. Our hypothesis is that removal of HP1 protein to
the nuclear periphery might be an important step for
rapid gene induction and efficient initiation of T3-medi-
ated transcription. In this regard, it has been suggested
that the redistribution of HP1 would be in accordance
with the radial arrangement of the genome in the nucleus,
in which transcriptional silent chromatin is located near
the nuclear periphery and active loci are positioned more
interior (20, 21, 22). However, to confirm this hypothe-
sis, further experiments, such as FISH assays, will be nec-
essary to determine the nuclear localization of T3 acti-
vated and repressed genes.
Previous report have demonstrated that transcriptional
regulation by TR involves, in addition to the expected
changes in acetylation, methylation of H3-K4, H3-K9, and
H3-R17, and the dualmodification inH3-K14/H3-Ser10 in
xenopus oocytes (23). Moreover these authors demon-
strated that TR interacts with the methyltransferase
Suv39H1 that facilitates repression by unliganded TR.
Our experiments show a significant increase in total
amount of H3Ser10ph in response to T3 mediated by TR
receptor. Global histone changes have also been observed
by other authors (20, 24–26), however it is logical to
think that each gene may file different levels of such
changes. In fact we have observed that despite an overall
change in H3Ser10 phosphorylation of those genes that
are regulated by T3 such GH or PRL, the non–T3-regu-
lated gene, GAPDH, does not show any changes in the
levels of H3Ser10ph even after T3 induction.
Two additional reports have analyzed the mechanisms
by which steroid hormone–induced histone phosphoryla-
tion promotes transcriptional activation. Thus, proges-
terone appears to induce H3Ser10 phosphorylation pro-
moting release of HP1 from the target promoter (27),
whereas androgens would induce H3T11 and H3T6
phosphorylation enhancing H3K9 demethylation or in-
hibiting H3K4 demethylation, respectively (24, 28). In-
terestingly, our data show that in T3-regulated genes the
hormone induces both H3Ser10 phosphorylation and
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HP1 release. The enzymes that regulate nuclear recep-
tor–mediated histone phosphorylation differ from one li-
gand to the other. For example, progesterone induced
H3Ser10 phosphorylation through activation of MSK1,
while androgens mediate H3T11 and H3T6 phosphory-
lation through either the protein kinase C–related kinase
1 or protein kinase C beta I (PKC1) respectively. In our
study, we have analyzed the involvement of different ki-
nases, such as MSK1, RSK2, and Aurora kinase B using
specific inhibitors, and only the Aurora kinase B specific
inhibitor ZM443979 was able to inhibit T3 effects, indi-
cating that this kinase mediates T3-induced H3Ser10
phosphorylation. Strikingly, not only T3 but also estro-
gens are able to induce Aurora kinase B activity (10),
opening the possibility that other nuclear receptors li-
gands could regulate the activity of this kinase in a similar
manner. All these data demonstrate that different nuclear
receptors show selectivity for specific kinases that modu-
late the transcription of hormone target genes by regulat-
ing epigenetic marks such as histone phosphorylation at
different residues.
A novel function for the Aurora kinase B during
transcriptional activation
The role of Aurora kinase B during mitosis is well
established because this enzyme regulates cytokinesis at
G2/M. Aurora kinase B is part of the chromosomal pas-
senger complex that maintains the integrity of spindle
assembly checkpoint during cell cycle. In dividing cells,
Aurora kinase B is responsible for H3Ser10 phosphory-
lation, which in turn leads to the release of HP1 and to
chromatin changes necessary for chro-
mosome segregation (6, 7). Our data
show a novel transcriptional role for
Aurora kinase B, because activation of
this kinase is essential for TR-depen-
dent GH gene expression. We demon-
strated in vivo and in vitro the interac-
tion between TR and Aurora kinase B
in a ligand-independent manner as well
as the recruitment of Aurora kinase B
to the GH promoter region upon hor-
mone induction. A possible explana-
tion for the induction of Aurora kinase
B activity in response to T3 is that the
phosphorylated form of this kinase is
required for its promoter recruitment.
Alternatively, factors such as nuclear
receptor coactivators could be also me-
diate the interaction of Aurora kinase B
with promoter regions.
This transcriptional effect occurs in
nondividing cells at G0/G1, a cell-cycle
stage where several genes are reexpressed. In noncycling
differentiated plasma cells, high levels of H3Ser10 phos-
phorylation, generated by Aurora kinase B, have been
shown to lead the delocalization of HP1 away from
heterochromatin (16). These data together with our re-
sults, provide evidence that the role of Aurora kinase B is
not only restricted to mitosis. Our studies have been per-
formed in pituitary cells, but it could be interesting to
check the transcriptional role of Aurora kinase B in other
systems because overexpression of this kinase has been
observed in hepatocellular carcinoma (29), biliary tract
cancer (30), and acute myeloid leukemia among others
(31). In fact, Aurora kinase B inhibitors are being evalu-
ated in clinical trials for the treatment of cancer, because
they induce apoptosis in tumor cells. Aurora kinase B
could be an important regulator of genes implicated in
pathological situations such as cancer. In this regard, it
will be also necessary to perform microarray analyses in
T3-treated cell in the presence or absence of Aurora B
inhibitor to analyze which genes are transcriptionally
controlled by Aurora B.
Taken together, our data demonstrate a novel mecha-
nism bywhichT3-regulated gene transcription is controlled
by the Aurora kinase B. Aurora kinase B mediates the T3-
induced enhancement of histone H3Ser10 phosphorylation
and the dissociation of HP1 from chromatin, thereby fa-
cilitating efficient transcriptional initiation of T3-target
genes. The regulation of chromatin packaging with such a
model would provide a particularly flexible mechanism to
regulate genes that respond to hormone stimulus and are
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characterized by periods of induction followedby periods of
silencing.
Materials and Methods
Cell culture and transfections
HEK293T and GH4C1 cells were cultured in DMEM supple-
mentedwith10%fetal calf serum, and theywere transfectedby the
calcium phosphate method or electropora-
tion, respectively. The following amounts of
plasmid were used per well (60 mm): 5 g
DR4TK-luc, 0.6 g pRL-TK (renilla), 0.5 g
pSG5-TR, 25–100 ng pcDNA-FLAG-AKB,
and pcDNA–FLAG-AKB-K/R (K109R;
kinase-negative). After transfection, the cells
were preincubated for 48 h in DMEM sup-
plementedwith10%AG1-X8resin and char-
coal-stripped newborn calf serum, and then
they were exposed to 5 nM T3 (GH4C1) or
100 nM T3 (HEK293T) for different times
where appropriate. When indicated, 2 M
ZM447439 (Tocris), 5 M U0126 (Calbio-
chem), or1MSB203580 (Calbiochem)were
also added 30min before the T3. These prod-
ucts were diluted in DMSO. Luciferase and
renilla activity were assayedwith a dual lucif-
erase assay system (Promega). All experi-
ments were repeated at least three times in
duplicate, and all data are presented as the
mean SD.
Immunoprecipitation (IP) and
Western blot analyses
For Western blot assays, cells extracts
were prepared in lysis buffer [50 mM Tris
(pH 7.5), 150 mMNaCl, 0.5% SDS, 30 mM
PPi, 0.5 M NaF, and protease inhibitors]
and 5–10 g was loaded onto 10% or 15%
SDS gels. After the proteins were transferred
tomembranes, theywere probedwith the fol-
lowing antibodies: anti-phosphoSer10H3,
anti-H3 (Upstate Biotechnology), anti-HP1
(Chemicon), anti-TR (Santa Cruz) and anti-
Aurora B (Abcam) and anti-HA (Sigma). For
IP, GH4C1 cells extracts in buffer B [50 mM
HEPES (pH8), 600mMKCL, 0.5%N-P40, 1
mM Na3VO4, 1 mM DTT, protease inhibi-
tors]. These cell extracts (2 mg for each im-
munoprecipitation) were precleared for 2 h
with 40 l protein A agarose beads and incu-
bated overnight with 60 l protein A agarose
beads previously coupled with 2 g of the
specific antibody or rabbit IgG. The immuno-
precipitated proteins and 20 g of total ex-
tract as the input were analyzed by Western
blot using the antibodies indicated.
GST pull-down assays
Recombinant proteins were synthesized,
purified on glutathione–Sepharose resin,
and analyzed by SDS–PAGE. 35S-labeled Aurora B was gener-
ated with the TNT T7 Quick coupled in vitro transcription and
translation kit and used in pull-down assays with 1g of GST or
GST-fused proteins as described previously (32).
ChIP
ChIP experiments were essentially performed as described
in the Chromatin Immunoprecipitation Assay kit (Upstate,
Cat. 17-295) Sonication was performed using a Bioruptor
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treatment inhibits T3-induced transactivation. B, GH mRNA expression in GH4C1 cells, analyzed
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with expression plasmids for TR and increased amounts of Aurora kinase B. D, Expression vectors
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UCD-200TM (Diagenode) following the manufacturer’s in-
structions. GH4C1 cells were treated for 15 min in the pres-
ence or absence of T3 (5 nM), and IP was performed with the
specific antibodies indicated. Quantification of ChIP was per-
formed by real-time PCR, and the Ct values of the target
sequences in the immunoprecipitate were calculated in rela-
tion to the input (INP) fractions by the comparative Ct
method using the equation 2-[Ct(IP)-Ct(INP)]. Each of these val-
ues was referred to as the relative abundance with respect to
untreated cells. GAPDH promoter was used in all experi-
ments as negative control.
RNA interference experiments
Aurora-B siRNAs (2 M, Dharmacon) were transfected with
siPORT electroporation siRNA buffer (Ambion). GH4C1 cells
were transfected by electroporation, as previously described
(33). Briefly, 2–3 106 cells were mixed with reporter plasmids
and exposed to a high-voltage pulse (170 to 200 V, 960 F) in
a Bio-Rad electroporator with a capacitor extender (Bio-Rad
Laboratories, Richmond, CA). After 48 h, the medium was re-
placed by fresh medium with hormone-depleted serum, and af-
ter a further 24 h the cells were incubated with T3 for 15 min
before performing Western blot analysis or for 8 h before car-
rying out RT-PCR assays. The decrease in the levels of Aurora-B
was confirmed by Western blot assays.
Quantitative RT-PCR (QRT-PCR)
DNAse-treated RNA (2 g) isolated using TRI Reagent
(Sigma) was reverse transcribed with the SuperScript First
Strand Synthesis System (Invitrogen Life Technologies) accord-
ing the manufacturer’s instructions. The resulting cDNA tem-
plate (2 l) was amplified with specific primers using the 2
Brilliant SYBR Green QPCR Kit (Stratagene). Product forma-
tion was detected by the incorporation of SYBR green I using
ROX as a passive reference. Each value was normalized against
the GAPDH gene and expressed as relative RNA abundance
over time zero. Experiments were repeated at least three
times and the primers used were as follows: GAPDH, forward
(5-ACACTGCATGCCATCACTGCC-3), reverse (5-GCCT-
GCTTCACCACCTTCTTG-3); GH, forward (5-CTGGCT-
GCTGACACCTACAA-3  ) , reverse (5  -AAGCGA-
AGCAATTCCATGTC-3).
Kinase assay
GH4C1 cells were incubated for 15 min with T3 (5 nM).
Aurora-B was then immunoprecipitated and incubated with H3
histone (10 g, Roche) for 30 min at 30 C in kinase assay buffer
[20mMHEPES (pH7.4), 150mMKCl, 5mMMnCl2, 5mMNaF,
1 mM DTT, 140 M cold ATP] in the presence or absence of T3
(50 nM). H3Ser10ph levels were detected by Western blotting
with the specific antibody.
Immunofluorescence
GH4C1 cells were fixedwith 4% formaldehyde for 10min at
room temperature and permeabilizedwith PBS containing 0.5%
Triton for 10 min at room temperature. Slides were incubated
overnight in antibody dilution buffer (1 phosphate-buffered
saline, 1% BSA, 0.05% Triton X-100) containing the primary
antibodies diluted 1:100 (anti-H3Ser10ph), 1:100 (anti-HP1),
or 1:500 (anti-HA). After incubation, the slides were washed
three times in antibody dilution buffer and incubatedwith Alexa
Fluor 488- and 546-conjugated antibodies (1:500, Molecular
Probes). The slides were washed three times in PBS, stained with
DAPI (0.5 g/ml), and mounted in vectashield antifade mount-
ing medium (Vector Laboratories) to be analyzed by confocal
microscopy. Confocal images were taken using a 63/1.4–0.6
OIL on Leica microscope with the TCS SP2 confocal system.
The projection images were produced using the Leica LCS
software.
Cell-cycle analysis
GH4C1 cells were grown for 48 h in DMEMwith hormone-
depleted serum and incubated in the presence or absence of T3
for 15min. Cells were collected and fixed in 70% ethanol for 15
min, incubated with RNase (1 mg/ml) at 37 C for 30 min, and
labeledwith400l propidium iodide (50g/ml) for at least 15min
at room temperature. Cell-cycle profiles were determined by flow-
cytometry on a FACScan flow cytometer, and the proportion of cells
in the different phases was calculated from the DNA histograms.
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